GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

CONCLUSION: GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.PMID:36800286 | DOI:10.1210/clinem/dgad076

Source: The Journal of Clinical Endocrinology and Metabolism - February 17, 2023 Category: Endocrinology Authors: Mainak Banerjee Rimesh Pal Satinath Mukhopadhyay Kirthana Nair Source Type: research